As if last week's Jardiance news wasn't enough to worry makers of DPP-4 diabetes drugs, the FDA has now issued a warning that the class of meds might cause "severe and disabling" joint pain.
Back in June, researchers unveiled details of the ELIXA trial, which put Sanofi's Lyxumia in the clear as far as cardiovascular safety risks go. Now, a new analysis of the study shows that in Type 2 patients with acute coronary syndrome, the diabetes med didn't increase the rate of cardiovascular events--but it didn't decrease it, either.
Europeans have had a bone to pick with companies supplying death penalty drugs to U.S. prisons, with government officials restricting exports and prompting shortages. Now a Dutch pension fund is selling out of Mylan, after discovering that one of its products is stocked at a U.S. prison that carries out executions.
Baxalta may not want to be snatched up at its young age, as it told Irish suitor Shire early this month. But that doesn't mean it doesn't want to land some deals itself--and Ariad Pharmaceuticals may be on its radar.
The good news keeps rolling in for Merck when it comes to the cardiovascular safety of its DPP-4 inhibitor, Januvia. According to a new analysis of the TECOS trial, patients with Type 2 diabetes and cardiovascular disease--even those with a history of heart failure--can take the drug without an increased risk of CV complications.
Good news for partners Bristol-Myers Squibb and Pfizer: In a Phase IV study of their new-age anticoagulant, Eliquis, atrial fibrillation patients posted adherence rates near 90%. And the icing on the cake? The company didn't need to shell out on patient education to get them there.
It was attention-grabbing when California sued a handful of drugmakers, accusing them of lying about the safety of their high-powered painkillers and blaming them for an epidemic of prescription drug overdoses and a resurgence in heroin use. But from a legal standpoint, a California judge has ruled, there is not much there to stand on.
Pfizer has no problem keeping sales for Viagra flying high in China, where brand awareness campaigns and changing attitudes toward sex have given it a sizable hold on the ED market. But the company is facing some headwind in the country, as Chinese marketing authorities slapped Pfizer with a fine for paying local drugstores to promote its blockbuster ED med.
Celgene Thursday reported that it had completed its $7.2 billion buyout of Receptos. Celgene agreed to pay $232 per share for the San Diego-headquartered company, a nearly 18% premium.
Mylan's shareholders think it is a dandy idea to continue to pursue a takeover of Perrigo. Two thirds of those who voted today favored pursuing the buyout of over-the-counter specialist despite the adamant opposition to the deal from Perrigo CEO Joseph Papa and his board.
New Jersey-based pharma giant Johnson & Johnson already has a presence in Florida, but it's about to get bigger--by 500 jobs.
Meda is no stranger to the M&A arena, last year inking a pact to buy Italy's Rottapharm. This time, though, it could wind up on the other side of the bargaining table.
After announcing a $2 billion manufacturing investment Wednesday--and launching a late-stage trial of its oral semaglutide drug to boot--the Danish drugmaker now says it's buying two private biopharma research companies specializing in diabetes and related metabolic problems.
After much industry lobbying and public debate, the FDA has proposed a system for naming biosimilar drugs. It's a sort of hybrid of the generic name on one hand and the unique brand name on the other. And it would allow the FDA to make some biosims easy to substitute for the brand-name original--and others not so easy.
AbbVie escaped the wrath of the FTC in a pay-for-delay suit over AndroGel generics, as a federal judge who previously threw out antitrust claims against the company rejected the agency's attempts to reconsider its case.
Early this month, Horizon Pharma wrote to hostile target Depomed to get the ball rolling on requesting a special shareholders' meeting. And it's not happy about how that process has gone so far.
It's happened: Eli Lilly & Co. and Boehringer Ingelheim have rolled out their biosimilar version of Lantus in its first major market. The U.K. launch follows some smaller rollouts in Eastern Europe--and it's the next move in a planned worldwide assault on the Sanofi diabetes stalwart.
Pfizer's new breast-cancer-fighter, Ibrance, has gotten off to a quick start in patients with advanced breast cancer. And now, the company is embarking on a study to see whether it can work earlier in the disease, too.
With a game-changing oral diabetes treatment moving through clinical trials, Novo Nordisk will spend about $1.2 billion on its first API plant in the U.S., a project that is expected to bring 700 jobs. As part of the 5-year project, it will also expand a plant in Denmark.
Medivation made a name for itself with Xtandi, the prostate cancer med that's now giving Johnson & Johnson's Zytiga a run for its money. Now, it wants to challenge other drugmakers in the PARP inhibitor field, too.